Belite Bio, Inc
NASDAQ: BLTE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yu-Hsin Lin
- Employees
- 25
- Headquarters
- San Diego, United States
- IPO year
- 2022
- Market cap
- $5.9B
- Website
- https://belitebio.com
Loading BLTE…
Loading profile data…Frequently asked questions about BLTE
What does Belite Bio, Inc (BLTE) do?
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once...
Where does BLTE trade?
Belite Bio, Inc (BLTE) trades on the NASDAQ Capital Market.
What sector is BLTE in?
Belite Bio, Inc (BLTE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Belite Bio, Inc?
Yu-Hsin Lin is the chief executive officer of Belite Bio, Inc (BLTE).
Where is Belite Bio, Inc headquartered?
Belite Bio, Inc is headquartered in United States.
Does BLTE pay a dividend?
Belite Bio, Inc (BLTE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BLTE go public?
Belite Bio, Inc (BLTE) completed its initial public offering in 2022.
Is BLTE an ADR?
Yes — BLTE is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Belite Bio, Inc reporting and dividends follow the underlying issuer.